Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With McArdle Disease (Glycogen Storage Disorder 5)

Next Previous
Trial Profile

A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With McArdle Disease (Glycogen Storage Disorder 5)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavodelpar (Primary)
  • Indications Glycogen storage disease type V
  • Focus Adverse reactions
  • Sponsors Reneo Pharmaceuticals

Most Recent Events

  • 15 Jun 2023 According to a Reneo Pharmaceuticals media release, results from the study will be presented at the 2023 Mitochondrial Medicine Symposium.
  • 29 Aug 2022 According to a Reneo Pharmaceuticals media release, results from the study were presented in a poster at the International Network for Fatty Acid Oxidation Research and Management (INFORM) annual meeting, being held in Freiburg, Germany August 28-29, 2022.
  • 23 Mar 2022 According to a Reneo Pharmaceuticals media release, 17 patients were enrolled in the 12-week open-label McArdle Phase 1b study

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top